|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 354.75 INR | -0.74% |
|
+0.77% | -13.86% |
| 07/03 | Pinnacle Life Science Pvt. Ltd announced that it expects to receive INR 100 million in funding from Aarti Drugs Limited | CI |
| 04/02 | Aarti Drugs Limited, Q3 2026 Earnings Call, Feb 04, 2026 |
| Fiscal Period: March | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | 14.51 | 9.07 | 6.93 | 6.82 | 5.77 | |||||
Return on Total Capital | 21.05 | 12.68 | 9.49 | 9.08 | 7.55 | |||||
Return On Equity % | 35.81 | 21.03 | 14.93 | 13.87 | 12.68 | |||||
Return on Common Equity | 35.81 | 21.03 | 14.92 | 13.86 | 12.69 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 38.19 | 31.6 | 29.67 | 32.89 | 34.59 | |||||
SG&A Margin | 3.78 | 3.38 | 3.43 | 4.14 | 4.78 | |||||
EBITDA Margin % | 20.11 | 13.47 | 11.21 | 12.42 | 11.91 | |||||
EBITA Margin % | 18.01 | 11.59 | 9.45 | 10.48 | 9.63 | |||||
EBIT Margin % | 18.01 | 11.59 | 9.45 | 10.48 | 9.69 | |||||
Income From Continuing Operations Margin % | 13.01 | 8.24 | 6.12 | 6.79 | 7.04 | |||||
Net Income Margin % | 13.01 | 8.24 | 6.12 | 6.78 | 7.04 | |||||
Net Avail. For Common Margin % | 13.01 | 8.24 | 6.12 | 6.78 | 7.04 | |||||
Normalized Net Income Margin | 10.7 | 6.78 | 5.16 | 5.81 | 5.55 | |||||
Levered Free Cash Flow Margin | 0.7 | -4.7 | -3.53 | 4.06 | -0.63 | |||||
Unlevered Free Cash Flow Margin | 1.37 | -4.18 | -2.76 | 4.89 | 0.31 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 1.29 | 1.25 | 1.17 | 1.04 | 0.95 | |||||
Fixed Assets Turnover | 3.22 | 3.43 | 3.29 | 2.67 | 2.2 | |||||
Receivables Turnover (Average Receivables) | 4.13 | 3.81 | 3.36 | 3.22 | 3.28 | |||||
Inventory Turnover (Average Inventory) | 3.6 | 3.62 | 3.67 | 3.39 | 3.26 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 1.78 | 1.48 | 1.6 | 1.66 | 1.6 | |||||
Quick Ratio | 0.97 | 0.84 | 0.95 | 0.92 | 0.95 | |||||
Operating Cash Flow to Current Liabilities | 0.26 | 0.07 | 0.14 | 0.45 | 0.29 | |||||
Days Sales Outstanding (Average Receivables) | 88.41 | 95.71 | 108.5 | 113.58 | 111.3 | |||||
Days Outstanding Inventory (Average Inventory) | 101.45 | 100.89 | 99.57 | 108.08 | 112.07 | |||||
Average Days Payable Outstanding | 84.67 | 80.39 | 91.12 | 103.45 | 104.13 | |||||
Cash Conversion Cycle (Average Days) | 105.19 | 116.21 | 116.95 | 118.2 | 119.23 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 38.4 | 52.38 | 51.05 | 44.02 | 44.92 | |||||
Total Debt / Total Capital | 27.75 | 34.37 | 33.8 | 30.56 | 31 | |||||
LT Debt/Equity | 16.55 | 13.55 | 17.2 | 21.55 | 20.86 | |||||
Long-Term Debt / Total Capital | 11.96 | 8.89 | 11.38 | 14.96 | 14.39 | |||||
Total Liabilities / Total Assets | 48.28 | 53.07 | 50.74 | 47.3 | 46.81 | |||||
EBIT / Interest Expense | 16.91 | 13.9 | 7.71 | 7.91 | 6.45 | |||||
EBITDA / Interest Expense | 19.03 | 16.31 | 9.22 | 9.43 | 7.96 | |||||
(EBITDA - Capex) / Interest Expense | 15.19 | 8.98 | 4.27 | 2.68 | 3.02 | |||||
Total Debt / EBITDA | 0.8 | 1.6 | 1.98 | 1.79 | 2.15 | |||||
Net Debt / EBITDA | 0.75 | 1.5 | 1.92 | 1.72 | 2.08 | |||||
Total Debt / (EBITDA - Capex) | 1.01 | 2.91 | 4.28 | 6.29 | 5.68 | |||||
Net Debt / (EBITDA - Capex) | 0.94 | 2.73 | 4.14 | 6.06 | 5.47 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 19.31 | 15.49 | 9.14 | -6.9 | -5.6 | |||||
Gross Profit, 1 Yr. Growth % | 33.05 | -4.43 | 2.46 | 3.2 | -0.72 | |||||
EBITDA, 1 Yr. Growth % | 68.83 | -22.64 | -9.21 | 3.69 | -9.45 | |||||
EBITA, 1 Yr. Growth % | 81.86 | -25.7 | -10.96 | 3.81 | -13.29 | |||||
EBIT, 1 Yr. Growth % | 81.86 | -25.7 | -10.96 | 3.81 | -12.73 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | 98.3 | -26.89 | -18.85 | 3.15 | -2.04 | |||||
Net Income, 1 Yr. Growth % | 98.31 | -26.88 | -18.89 | 3.07 | -1.9 | |||||
Normalized Net Income, 1 Yr. Growth % | 103.96 | -26.79 | -17.01 | 4.97 | -9.94 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % | 98.31 | -26.41 | -18.89 | 3.82 | -1.19 | |||||
Accounts Receivable, 1 Yr. Growth % | 13.63 | 35.06 | 15.33 | -18.53 | 6.62 | |||||
Inventory, 1 Yr. Growth % | 27.53 | 26.73 | -1.84 | -5.89 | -2.67 | |||||
Net Property, Plant and Equip., 1 Yr. Growth % | 4.56 | 12 | 15.56 | 20.05 | 9.46 | |||||
Total Assets, 1 Yr. Growth % | 12.02 | 25.02 | 9.67 | 0.45 | 5.85 | |||||
Tangible Book Value, 1 Yr. Growth % | 40.27 | 13.47 | 15 | 6.56 | 4.91 | |||||
Common Equity, 1 Yr. Growth % | 39.99 | 13.46 | 15.06 | 7.47 | 6.82 | |||||
Cash From Operations, 1 Yr. Growth % | -38.24 | -55.06 | 90.59 | 169.22 | -31.86 | |||||
Capital Expenditures, 1 Yr. Growth % | 83.64 | 72.25 | 8.45 | 37.32 | -21.73 | |||||
Levered Free Cash Flow, 1 Yr. Growth % | -88.08 | -879.36 | -18.08 | -228.07 | -114.62 | |||||
Unlevered Free Cash Flow, 1 Yr. Growth % | -80.07 | -454.23 | -27.88 | -308.16 | -94.02 | |||||
Dividend Per Share, 1 Yr. Growth % | 400 | -60 | 0 | 0 | 0 | |||||
Compound Annual Growth Rate Over Two Years | ||||||||||
Total Revenues, 2 Yr. CAGR % | 17.49 | 17.38 | 12.27 | 0.8 | -6.25 | |||||
Gross Profit, 2 Yr. CAGR % | 28.97 | 12.76 | -1.04 | 2.83 | 1.22 | |||||
EBITDA, 2 Yr. CAGR % | 44.75 | 14.29 | -16.19 | -3.23 | -3.1 | |||||
EBITA, 2 Yr. CAGR % | 52.88 | 16.24 | -18.66 | -4.14 | -5.12 | |||||
EBIT, 2 Yr. CAGR % | 52.88 | 16.24 | -18.66 | -4.14 | -4.82 | |||||
Earnings From Cont. Operations, 2 Yr. CAGR % | 76.75 | 20.41 | -22.97 | -8.51 | 0.52 | |||||
Net Income, 2 Yr. CAGR % | 76.76 | 20.42 | -22.99 | -8.57 | 0.55 | |||||
Normalized Net Income, 2 Yr. CAGR % | 70.24 | 22.2 | -22.05 | -6.66 | -2.77 | |||||
Diluted EPS Before Extra, 2 Yr. CAGR % | 77.82 | 20.81 | -22.74 | -8.24 | 1.28 | |||||
Accounts Receivable, 2 Yr. CAGR % | 10.04 | 23.88 | 24.8 | -3.07 | -6.8 | |||||
Inventory, 2 Yr. CAGR % | 29.72 | 27.13 | 11.54 | -3.88 | -4.29 | |||||
Net Property, Plant and Equip., 2 Yr. CAGR % | 2.24 | 8.22 | 13.76 | 16.21 | 14.64 | |||||
Total Assets, 2 Yr. CAGR % | 10.15 | 18.34 | 17.09 | 4.96 | 3.12 | |||||
Tangible Book Value, 2 Yr. CAGR % | 29.98 | 26.16 | 14.23 | 9.6 | 5.73 | |||||
Common Equity, 2 Yr. CAGR % | 29.65 | 26.03 | 14.26 | 11.2 | 7.15 | |||||
Cash From Operations, 2 Yr. CAGR % | 4.03 | -47.3 | -6.94 | 125.77 | 35.45 | |||||
Capital Expenditures, 2 Yr. CAGR % | 8.93 | 77.95 | 36.68 | 22.04 | 3.68 | |||||
Levered Free Cash Flow, 2 Yr. CAGR % | 1.69 | -3.93 | 152.68 | -6.26 | -56.73 | |||||
Unlevered Free Cash Flow, 2 Yr. CAGR % | -13.74 | -16.12 | 59.84 | 9.07 | -64.72 | |||||
Dividend Per Share, 2 Yr. CAGR % | 216.23 | 41.42 | -36.75 | 0 | 0 | |||||
Compound Annual Growth Rate Over Three Years | ||||||||||
Total Revenues, 3 Yr. CAGR % | 20.11 | 16.82 | 14.57 | 5.48 | -1.38 | |||||
Gross Profit, 3 Yr. CAGR % | 21.84 | 16.71 | 9.22 | 0.35 | 1.63 | |||||
EBITDA, 3 Yr. CAGR % | 30.04 | 17.47 | 5.85 | -10.19 | -5.35 | |||||
EBITA, 3 Yr. CAGR % | 34.72 | 20.2 | 6.36 | -11.94 | -7.29 | |||||
EBIT, 3 Yr. CAGR % | 34.72 | 20.2 | 6.36 | -11.94 | -7.09 | |||||
Earnings From Cont. Operations, 3 Yr. CAGR % | 50.47 | 31.69 | 5.57 | -15.1 | -6.4 | |||||
Net Income, 3 Yr. CAGR % | 50.47 | 31.7 | 5.56 | -15.13 | -6.4 | |||||
Normalized Net Income, 3 Yr. CAGR % | 43.62 | 28.5 | 7.41 | -13.92 | -7.77 | |||||
Diluted EPS Before Extra, 3 Yr. CAGR % | 51.08 | 32.52 | 5.78 | -14.74 | -5.94 | |||||
Accounts Receivable, 3 Yr. CAGR % | 13.98 | 17.82 | 20.96 | 8.26 | 0.06 | |||||
Inventory, 3 Yr. CAGR % | 14.26 | 28.72 | 16.63 | 5.4 | -3.48 | |||||
Net Property, Plant and Equip., 3 Yr. CAGR % | 3 | 5.4 | 10.61 | 14.79 | 13.92 | |||||
Total Assets, 3 Yr. CAGR % | 8.32 | 14.9 | 15.38 | 11.26 | 5.26 | |||||
Tangible Book Value, 3 Yr. CAGR % | 26.52 | 24.22 | 22.33 | 10.88 | 8.01 | |||||
Common Equity, 3 Yr. CAGR % | 26.11 | 24.01 | 22.26 | 11.95 | 9.72 | |||||
Cash From Operations, 3 Yr. CAGR % | 30.44 | -21.34 | -18.81 | 32.31 | 51.45 | |||||
Capital Expenditures, 3 Yr. CAGR % | 5.75 | 26.95 | 50.87 | 36.89 | 5.24 | |||||
Levered Free Cash Flow, 3 Yr. CAGR % | -36.71 | 100.05 | -8.9 | 89.9 | -49.54 | |||||
Unlevered Free Cash Flow, 3 Yr. CAGR % | -7.93 | 37.98 | -20.24 | 61.53 | -58.57 | |||||
Dividend Per Share, 3 Yr. CAGR % | 115.44 | 58.74 | 25.99 | -26.32 | 0 | |||||
Compound Annual Growth Rate Over Five Years | ||||||||||
Total Revenues, 5 Yr. CAGR % | 13.68 | 15.8 | 16.91 | 10.13 | 5.74 | |||||
Gross Profit, 5 Yr. CAGR % | 17.68 | 13.93 | 12.11 | 10.95 | 5.95 | |||||
EBITDA, 5 Yr. CAGR % | 20.64 | 12.25 | 9.09 | 8.7 | 2.07 | |||||
EBITA, 5 Yr. CAGR % | 23.52 | 13.71 | 10.1 | 9.8 | 1.49 | |||||
EBIT, 5 Yr. CAGR % | 23.52 | 13.71 | 10.1 | 9.8 | 1.62 | |||||
Earnings From Cont. Operations, 5 Yr. CAGR % | 32.47 | 20.17 | 15.11 | 13.84 | 3.52 | |||||
Net Income, 5 Yr. CAGR % | 32.48 | 20.18 | 15.11 | 13.82 | 3.53 | |||||
Normalized Net Income, 5 Yr. CAGR % | 32.07 | 18.45 | 12.47 | 13.08 | 3.22 | |||||
Diluted EPS Before Extra, 5 Yr. CAGR % | 33.5 | 20.9 | 15.53 | 14.4 | 3.96 | |||||
Accounts Receivable, 5 Yr. CAGR % | 10.85 | 20.37 | 18.19 | 8.97 | 8.98 | |||||
Inventory, 5 Yr. CAGR % | 18.4 | 20.2 | 13.16 | 14.53 | 7.76 | |||||
Net Property, Plant and Equip., 5 Yr. CAGR % | 5.63 | 5.4 | 7.18 | 9.6 | 11.6 | |||||
Total Assets, 5 Yr. CAGR % | 9.89 | 13.14 | 11.75 | 10.82 | 10.31 | |||||
Tangible Book Value, 5 Yr. CAGR % | 21.12 | 21.33 | 21.45 | 18.15 | 14.94 | |||||
Common Equity, 5 Yr. CAGR % | 20.64 | 20.97 | 21.23 | 18.72 | 15.98 | |||||
Cash From Operations, 5 Yr. CAGR % | 3.04 | -16.81 | 13.98 | 20.19 | -0.5 | |||||
Capital Expenditures, 5 Yr. CAGR % | -2.43 | 6.91 | 17.2 | 24.96 | 29.85 | |||||
Levered Free Cash Flow, 5 Yr. CAGR % | -14.04 | 119.73 | 9.96 | 47.72 | -34.72 | |||||
Unlevered Free Cash Flow, 5 Yr. CAGR % | 43.97 | 32.94 | 14.72 | 25.6 | -45.06 | |||||
Dividend Per Share, 5 Yr. CAGR % | 8.18 | 31.95 | 31.95 | 31.95 | 14.87 |
- Stock Market
- Equities
- AARTIDRUGS Stock
- Financials Aarti Drugs Limited
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















